TrialNature cancer2025
Odronextamab monotherapy in patients with relapsed/refractory diffuse large B cell lymphoma: primary efficacy and safety analysis in phase 2 ELM-2 trial.
Won Seog Kim et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
38 papers cite it
this paperpooled ittrialcites it